<DOC>
	<DOCNO>NCT00743964</DOCNO>
	<brief_summary>Recently , 3-drug ( ECX ) 2-drug ( CX ) combination chemotherapy involve capecitabine show promising result randomize clinical trial advance gastric cancer ( AGC ) . The objective study evaluate safety activity ECX CX combination chemotherapy give first-line therapy AGC .</brief_summary>
	<brief_title>Phase II Study Epirubicin , Cisplatin Capecitabine ( ECX ) Versus Cisplatin Capecitabine ( CX ) Advanced Gastric Cancer ( AGC )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Aged 75 year less Adenocarcinoma stomach Advanced , metastatic , recurrent No prio chemotherapy advance disease Adequate performance status Adequate major organ function Severe comorbid illness active infection Pregnancy lactate woman GI obstruction malabsorption syndrome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>